Repligen (NASDAQ:RGEN) Trading 6.1% Higher – Time to Buy?

Repligen Co. (NASDAQ:RGEN)’s stock price rose 6.1% during trading on Wednesday . The company traded as high as $136.85 and last traded at $136.27. Approximately 327,141 shares traded hands during trading, a decline of 51% from the average daily volume of 667,443 shares. The stock had previously closed at $128.49.

Analyst Ratings Changes

Several brokerages have recently issued reports on RGEN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company started coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Finally, UBS Group dropped their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Trading Up 8.1 %

The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.78 billion, a price-to-earnings ratio of -373.83, a price-to-earnings-growth ratio of 3.75 and a beta of 0.96. The firm’s 50 day moving average is $140.30 and its 200 day moving average is $143.67.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.23 EPS. Equities analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently modified their holdings of the business. Coldstream Capital Management Inc. grew its stake in shares of Repligen by 11.8% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,194 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 231 shares during the period. Resources Management Corp CT ADV bought a new stake in shares of Repligen during the 3rd quarter worth about $37,000. M&T Bank Corp raised its position in shares of Repligen by 5.9% during the third quarter. M&T Bank Corp now owns 3,166 shares of the biotechnology company’s stock valued at $471,000 after buying an additional 177 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Repligen during the 3rd quarter worth $658,000. Finally, MML Investors Services LLC raised its stake in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after buying an additional 89 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.